Fulvestrant Pharmaceutical Composition
Summary
EPO published patent application EP4074304A1 by Shanghai Bocimed Pharmaceutical Co., Ltd. for a fulvestrant pharmaceutical composition with preparation method. The application covers the antineoplastic drug formulation (A61P 35/00) and is published with examination complete, granting enforceable patent rights across 38 designated EU member states and extension states.
What changed
EPO published patent application EP4074304A1 for a fulvestrant pharmaceutical composition filed by Shanghai Bocimed Pharmaceutical Co., Ltd. The patent covers the drug formulation (A61K 31/565 active ingredient), preparation method, and applications for cancer treatment (A61P 35/00). The A1 publication indicates the application has passed substantive examination and been found allowable.
For pharmaceutical companies and manufacturers, this patent grants Shanghai Bocimed exclusive rights to the specified fulvestrant formulation across 38 designated Contracting States including all major EU markets. Competitors developing generic fulvestrant products must design around these claims or pursue licensing. The patent's validity period runs 20 years from the filing date, affecting market entry timelines for competing formulations.
What to do next
- Monitor patent expiration date for freedom-to-operate decisions
- Review composition claims for potential licensing opportunities
- Update IP portfolio records with new patent reference
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FULVESTRANT PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
Publication EP4074304A1 Kind: A1 Apr 01, 2026
Applicants
Shanghai Bocimed Pharmaceutical Co., Ltd.
Inventors
YING, Shuhuan, LI, Hong, CHEN, Zhixiang, WANG, Tingting
IPC Classifications
A61K 9/10 20060101AFI20231201BHEP A61K 9/14 20060101ALI20231201BHEP A61K 47/38 20060101ALI20231201BHEP A61K 31/565 20060101ALI20231201BHEP A61P 35/00 20060101ALI20231201BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.